Amedeo Smart

Free Medical Literature Service

 

Amedeo

Colorectal Neoplasms
  Free Subscription

Articles published in
Ann Oncol
    July 2024
  1. BIONDO S, Frago R, Kreisler E
    Primary tumor resection for asymptomatic colorectal cancer with unresectable metastasis: the end of the dilemma.
    Ann Oncol. 2024 Jul 3:S0923-7534(24)00767-1. doi: 10.1016/j.annonc.2024.
    >> Share

  2. CECCHINI M, Sundar R
    Proofreading the way: immune checkpoint inhibitors in polymerase epsilon/polymerase delta (POLE/POLD1)-altered colorectal cancer.
    Ann Oncol. 2024;35:582-584.
    >> Share

    June 2024
  3. VAN DER KRUIJSSEN DEW, Elias SG, van de Ven PM, van Rooijen KL, et al
    Upfront resection versus no resection of the primary tumor in patients with synchronous metastatic colorectal cancer: the randomized phase 3 CAIRO4 study conducted by the Dutch Colorectal Cancer Group and the Danish Colorectal Cancer Group.
    Ann Oncol. 2024 Jun 7:S0923-7534(24)00722-1. doi: 10.1016/j.annonc.2024.
    >> Share

    May 2024
  4. AMBROSINI M, Rousseau B, Manca P, Artz O, et al
    Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic colorectal cancer.
    Ann Oncol. 2024 May 3:S0923-7534(24)00104-2. doi: 10.1016/j.annonc.2024.
    >> Share

  5. BRENNER H, Niedermaier T, Hoffmeister M
    Sensitivity of a blood ctDNA-based multimodal test for the detection of advanced colorectal neoplasms.
    Ann Oncol. 2024;35:476-477.
    >> Share

    April 2024
  6. KELSEN D, Ben-Aharon I, Gordon N
    Identifying Genetic Loci Associated with an Increased Risk for Early Onset Colorectal Cancer.
    Ann Oncol. 2024 Apr 3:S0923-7534(24)00106-6. doi: 10.1016/j.annonc.2024.
    >> Share

    February 2024
  7. LASKAR RS, Qu C, Huyghe JR, Harrison T, et al
    Genome-wide association study and Mendelian randomization analyses provide insights into the causes of early-onset colorectal cancer.
    Ann Oncol. 2024 Feb 24:S0923-7534(24)00058-9. doi: 10.1016/j.annonc.2024.
    >> Share

    January 2024
  8. SANTUCCI C, Mignozzi S, Malvezzi M, Boffetta P, et al
    European cancer mortality predictions for the year 2024 with focus on colorectal cancer.
    Ann Oncol. 2024 Jan 17:S0923-7534(23)05110-4. doi: 10.1016/j.annonc.2023.
    >> Share

    November 2023
  9. HENRIKSEN TV, Demuth C, Frydendahl A, Nors J, et al
    Unraveling the potential clinical utility of circulating tumor DNA detection in colorectal cancer - evaluation in a nationwide Danish cohort.
    Ann Oncol. 2023 Nov 20:S0923-7534(23)05073-1. doi: 10.1016/j.annonc.2023.
    >> Share

  10. CERVANTES A, Martinelli E
    Updated treatment recommendation for third-line treatment in advanced colorectal cancer from the ESMO Metastatic Colorectal Cancer Living Guideline.
    Ann Oncol. 2023 Nov 7:S0923-7534(23)04335-1. doi: 10.1016/j.annonc.2023.
    >> Share

  11. DIENSTMANN R
    Time to start testing KRAS and BRAF V600E mutations in stage III colon cancer? Not in routine care, yet in clinical trials.
    Ann Oncol. 2023;34:962-963.
    >> Share

    October 2023
  12. ROS J, Vivancos A, Tabernero J, Elez E, et al
    Circulating tumor DNA, and clinical features to guide rechallenge with BRAF inhibitors in BRAF-V600E mutated metastatic colorectal cancer.
    Ann Oncol. 2023 Oct 20:S0923-7534(23)04326-0. doi: 10.1016/j.annonc.2023.
    >> Share

  13. BESSA X, Vidal J J, Balboa JC, Marquez C, et al
    High accuracy of a blood ctDNA-based multimodal test to detect colorectal cancer.
    Ann Oncol. 2023 Oct 5:S0923-7534(23)04010-3. doi: 10.1016/j.annonc.2023.09.3113.
    >> Share

    August 2023
  14. TAIEB J, Sinicrope FA, Pederson L, Lonardi S, et al
    Different prognostic values of KRAS exon 2 sub-mutations and BRAF V600E mutation in microsatellite stable (MSS) and unstable (MSI) stage III colon cancer: an ACCENT/IDEA pooled analysis of 7 trials.
    Ann Oncol. 2023 Aug 22:S0923-7534(23)00804-9. doi: 10.1016/j.annonc.2023.
    >> Share

    June 2023
  15. RATOVOMANANA T, Nicolle R, Cohen R, Diehl A, et al
    Prediction of Response to Immune Checkpoint Blockade in Patients with Metastatic Colorectal Cancer with Microsatellite Instability.
    Ann Oncol. 2023 Jun 1:S0923-7534(23)00695-6. doi: 10.1016/j.annonc.2023.
    >> Share

    April 2023
  16. SERRA-ARACIL X, Pericay C
    Reply to the Letter to the Editor 'The role of chemoradiotherapy in organ preservation for rectal cancer' by L. Xie, Q. Chen, and J. Zhu.
    Ann Oncol. 2023;34:440-442.
    >> Share

  17. DE WILT JHW, Bach SP
    Is it time for a paradigm shift in early rectal cancer treatment?
    Ann Oncol. 2023;34:336-338.
    >> Share

  18. XIE L, Chen Q, Zhu J
    The role of chemoradiotherapy in organ preservation for rectal cancer.
    Ann Oncol. 2023;34:440.
    >> Share

    March 2023
  19. ROS J, Matito J, Villacampa G, Comas R, et al
    Plasmatic BRAF-V600E allele fraction as a prognostic factor in metastatic colorectal cancer treated with BRAF combinatorial treatments.
    Ann Oncol. 2023 Mar 13:S0923-7534(23)00112-6. doi: 10.1016/j.annonc.2023.
    >> Share

    January 2023
  20. SERRA-ARACIL X, Pericay C, Badia-Closa J, Golda T, et al
    Short-term outcomes of chemoradiotherapy and local excision versus total mesorectal excision in T2-T3ab,N0,M0 rectal cancer: a multicentre randomised, controlled, phase III trial (the TAU-TEM study).
    Ann Oncol. 2023;34:78-90.
    >> Share

    November 2022
  21. SABERZADEH-ARDESTANI B, Foster NR, Lee HE, Shi Q, et al
    Association of tumor-infiltrating lymphocytes with survival depends on primary tumor sidedness in stage III colon cancers (NCCTG N0147) [Alliance].
    Ann Oncol. 2022;33:1159-1167.
    >> Share

    October 2022
  22. CERVANTES A, Adam R, Rosello S, Arnold D, et al
    Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up(dagger).
    Ann Oncol. 2022 Oct 19. pii: S0923-7534(22)04192.
    >> Share

    September 2022
  23. MORENO V, Salazar R, Gruber SB
    The prognostic value of TILs in stage III colon cancer must consider sidedness.
    Ann Oncol. 2022 Sep 16. pii: S0923-7534(22)04146.
    >> Share

    August 2022
  24. GLYNNE-JONES R, Harrison M
    Should the RAPIDO schedule represent standard of care in locally advanced rectal cancer?
    Ann Oncol. 2022;33:745-746.
    >> Share

  25. JIMENEZ-FONSECA P, Salazar R, Valenti V, Msaouel P, et al
    Is short-course radiotherapy and total neoadjuvant therapy the new standard of care in locally advanced rectal cancer? A sensitivity analysis of the RAPIDO clinical trial.
    Ann Oncol. 2022;33:786-793.
    >> Share

    June 2022
  26. ANDRE T, Lonardi S, Wong KYM, Lenz HJ, et al
    Nivolumab + low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142.
    Ann Oncol. 2022 Jun 25. pii: S0923-7534(22)01737.
    >> Share

  27. CICCOLINI J, Milano G
    Fewer cetuximab-related skin-toxicities in colorectal cancer patients treated with encorafenib: a Yin and Yang effect of ERK paradoxical activation.
    Ann Oncol. 2022 Jun 16. pii: S0923-7534(22)01729.
    >> Share

    March 2022
  28. BASILE D, Broudin C, Emile JF, Falcoz A, et al
    Tumor budding is an independent prognostic factor in stage III colon cancer patients: A post-hoc analysis of the IDEA-France phase III trial (PRODIGE-GERCOR).
    Ann Oncol. 2022 Mar 16. pii: S0923-7534(22)00379.
    >> Share

  29. DUCREUX M, Kim S, Borg C
    Selecting the right chemotherapy in first-line advanced squamous cell carcinoma of the anus.
    Ann Oncol. 2022;33:349-350.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016